The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
May 25, 2015
Omacetaxine (Synribo) for CML (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Omacetaxine (Synribo) for CML (online only)
May 25, 2015 (Issue: 1469)
The FDA has approved omacetaxine mepesuccinate
(Synribo – Teva), a cephalotaxine known for many
years as homoharringtonine, for treatment of adults
with chronic or accelerated phase chronic myeloid
leukemia (CML) who are no longer responding...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.